AI Article Synopsis
- * Out of these patients, six had to stop taking fingolimod, while six others were vaccinated against HPV, which was well-tolerated.
- * The study emphasizes the importance of screening for HPV and discussing vaccination options before starting fingolimod, along with the need for thorough evaluation of HPV disease if lesions appear during treatment, and calls for more prevalence studies among MS patients.
Article Abstract
Few cases of human papillomavirus (HPV) diseases have been reported in multiple sclerosis (MS) patients treated with fingolimod. We describe a case series of 16 MS patients (11 women, 5 men) developing HPV lesions after the onset of fingolimod, without previous HPV history. Fingolimod had to be discontinued in six patients. Six patients received vaccination for HPV, with good tolerance. Our report highlights that systematic HPV screening and discussion about HPV vaccination before fingolimod onset are crucial. In case of occurrence of HPV lesions during fingolimod treatment, a comprehensive workup of HPV disease is necessary, with discussion of HPV vaccination to prevent secondary lesions. Prevalence studies of HPV lesions are needed in MS patients with the different disease-modifying therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1352458521991433 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!